By Sarina Isaacs
American depositary receipts of EDAP slipped after the maker of robotic energy-based therapies posted a worse-than-expected loss for the first quarter.
EDAP's ADRs were recently down 21%, to $1.71, and have lost about three-quarters of their value over the past year.
The Vaulx-en-Velin, France, company on Thursday reported a first-quarter loss of $7.5 million, or 20 cents a share, compared with a loss of $4.9 million, or 13 cents a share, a year earlier.
Analysts were looking for a loss of 18 cents a share, according to FactSet.
Revenue fell to $14.3 million from $16.1 million in the prior year and below analysts' expectation of $16 million.
EDAP also reiterated its prior full-year guidance, expecting revenue growth of 16% to 25% in its core High Intensity Focused Ultrasound business and a decline of 20% to 25% for revenue in its non-core businesses.
Write to Sarina Isaacs at sarina.isaacs@wsj.com
(END) Dow Jones Newswires
May 15, 2025 13:57 ET (17:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.